Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 4/20 | 0.77 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.77 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.77 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.77 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.77 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.77 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.77 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.77 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.77 |
| ▸ | CPN1 | P15169 | 2/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18828823 | 1.00 | SLC6A1 (0.77) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL18828784 | 1.00 | SLC6A1 (0.77) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL5050450 | 0.98 | SLC6A1 (0.74) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL22323200 | 0.98 | SLC6A1 (0.74) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL4115452 | 0.98 | SLC6A1 (0.74) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL27564309 | 0.98 | SLC6A1 (0.74) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL15550547 | 0.98 | SLC6A1 (0.74) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Acetic Acid SCHEMBL28794935 | 0.94 | SLC6A1 (0.69) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL5501438 | 0.94 | SLC6A1 (0.74) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| Trifluoroacetic Acid SCHEMBL4096831 | 0.89 | SLC6A1 (0.62) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117050061-A | 2,4, 6-tri (piperidinecarboxylic acid) -1,3,5 triazine and preparation method thereof | 济南利恒生物科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-1374959-A | Piperidine quinolyl propyl derivatives, preparation method and compositions containing same | AVENTIS PHARMA SA (FR) | 2002-10-16 | — | — | CN | claimed |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-04-10 | — | — | US | disclosed |
| EP-4384520-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| CN-118076607-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-05-24 | — | — | CN | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| CN-117050061-A | 2,4, 6-tri (piperidinecarboxylic acid) -1,3,5 triazine and preparation method thereof | 济南利恒生物科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116969977-A | PAN-KRAS inhibitors | 北京华森英诺生物科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-28 | — | — | US | disclosed |
| EP-0789688-A1 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997009308-A1 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-03-13 | — | — | WO | disclosed |
| US-5583146-A | Heterocyclic thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| WO-1996031498-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | disclosed |
| EP-0501322-B1 | 3-Piperidinylmethylcarboxylate substituted indoles | GLAXO GROUP LTD (GB) | 1996-09-04 | — | — | EP | disclosed |
| EP-0623596-A1 | N-acylpyrrolidines or N-acylpiperidines having a guanidinyl- or amidinyl-substituted side chain as thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014745-A1 | USE OF 5-HT4 RECEPTOR ANTAGONISTS AS MEDICAMENTS FOR TREATING MIGRAINE | SMITHKLINE BEECHAM PLC (GB) | 1993-08-05 | — | — | WO | disclosed |
| WO-1992014727-A1 | 3-PIPERIDINYLMETHYLCARBOXYLATE SUBSTITUTED INDOLES | GLAXO GROUP LIMITED (GB) | 1992-09-03 | — | — | WO | disclosed |
| EP-0501322-A1 | 3-Piperidinylmethylcarboxylate substituted indoles | GLAXO GROUP LIMITED (GB) | 1992-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | SLC6A1 4346/4885SLC6A11 3584/4885SLC6A13 4335/4885 |
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | CMKLR1, CMKLR2, CCL2 | SLC6A1 4751/4885SLC6A11 4551/4885SLC6A13 4809/4885 |
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | SLC6A1 4466/4885SLC6A11 4286/4885SLC6A13 4375/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | SLC6A1 4016/4885SLC6A11 3639/4885SLC6A13 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.